Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227937 · ClinicalTrials.gov registry record
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
A clinical trial of Urinary Tract Infections, sponsored by Antonios Likourezos.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT05227937 is a study of Urinary Tract Infections that is actively recruiting participants, run by Antonios Likourezos. The registered enrollment target is 75 participants, below the 456-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05227937, a study of Urinary Tract Infections, is actively recruiting participants, sponsored by Antonios Likourezos.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.
Conditions Studied
Interventions
- DRUG Amikacin
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-09-21 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227937
The ClinicalTrials.gov registry entry for NCT05227937 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 456-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (84% lower). The listed sponsor is Antonios Likourezos, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Tract Infections appearing as the primary indexed condition, and to 1 intervention - of which Amikacin is the first listed.
NCT05227937 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05227937 about?
NCT05227937 is a clinical study titled "Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study". The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infe...
What is the current status of trial NCT05227937?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2022-09-21. Estimated completion is 2026-12-31.
What conditions does trial NCT05227937 study?
This clinical trial studies the following conditions: Urinary Tract Infections.
What interventions are being tested in trial NCT05227937?
The interventions under investigation include: Amikacin (DRUG).
Who is sponsoring clinical trial NCT05227937?
This trial is sponsored by Antonios Likourezos, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227937 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
RECRUITING · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
NextGen - Clinical Implication of Next Generation Sequencing
RECRUITING · Phase 4
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
RECRUITING · Phase 2
-
Double Voiding and Post-transplant UTI
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.